<SEC-DOCUMENT>0001213900-20-000438.txt : 20200108
<SEC-HEADER>0001213900-20-000438.hdr.sgml : 20200108
<ACCEPTANCE-DATETIME>20200107214302
ACCESSION NUMBER:		0001213900-20-000438
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20200108
FILED AS OF DATE:		20200108
DATE AS OF CHANGE:		20200107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immuron Ltd
		CENTRAL INDEX KEY:			0001660046
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38104
		FILM NUMBER:		20514450

	BUSINESS ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
		BUSINESS PHONE:		61 03 9824 5254

	MAIL ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k010820_immuronlimited.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the Month of January 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number: 001-38104</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>IMMURON LIMITED</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name of Registrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Level 3, 62 Lygon Street, Carlton
South, Victoria, 3053, Australia</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">Yes <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If &ldquo;Yes&rdquo; is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): 82-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IMMURON LIMITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXPLANATORY NOTE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immuron Limited (the &ldquo;Company&rdquo;) published one announcement
(the &ldquo;Public Notices&rdquo;) to the Australian Securities Exchange on January 8, 2020 titled:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD>&ldquo;Immuron CEO to present at Biotech Conference in SFO&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A copy of the Public Notice is attached
as an exhibit to this report on Form 6-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This report on Form 6-K (including the
exhibit hereto) shall not be deemed to be &ldquo;filed&rdquo; for purposes of the Securities Exchange Act of 1934, as amended (the
&ldquo;Exchange Act&rdquo;) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended,
except as shall be expressly set forth by specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; border-bottom: Black 1.5pt solid; padding-right: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Exhibit</B><BR>
<B>Number</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 91%; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; text-align: left; vertical-align: bottom"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt"><FONT STYLE="font-size: 10pt"><A HREF="f6k010820ex99-1_immuron.htm">Immuron CEO to present at Biotech Conference in SFO</A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>IMMURON LIMITED</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><IMG SRC="image_001.jpg" ALT="">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-size: 10pt">Date:&nbsp;&nbsp;January 8, 2020</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 37%; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Phillip Hains</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Phillip Hains</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Company Secretary</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">2</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>f6k010820ex99-1_immuron.htm
<DESCRIPTION>IMMURON CEO TO PRESENT AT BIOTECH CONFERENCE IN SFO
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="text-transform: uppercase">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Immuron CEO Dr.
Gary S. Jacob to Present at <BR>
Biotech Showcase Conference on January 13, 2020</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0"><B STYLE="font-size: 10pt">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Melbourne, Australia, January 8, 2020:
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral
immunoglobulin therapeutics for the treatment of gut mediated diseases, today announced that CEO Dr. Gary S. Jacob will present
at the Biotech Showcase Conference on Monday, January 13, 2020 at the Hilton Union Square hotel in San Francisco. Dr. Jacob&rsquo;s
presentation is scheduled for 10:00 am Eastern Standard Time in the Yosemite C room. Management will also be holding one-on-one
meetings with investors and analysts during the conference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ABOUT IMMURON</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immuron Limited (ASX: IMC, NASDAQ: IMRN),
is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies
for the treatment of inflammatory mediated and infectious diseases. Immuron has a novel technology platform with one commercial
asset Travelan&reg; generating revenue. Immuron&rsquo;s lead clinical candidate, IMM-124E, is presently being developed as a drug
to prevent TD. The Company also has a collaborative program with the U.S. Department of Defense (DoD) to develop treatments utilizing
the Company&rsquo;s hyperimmune bovine colostrum technology against enteric acute infectious pathogens, including Shigella and
Campylobacter. A recent USD $3.7 million grant was awarded by DoD to develop a product against Campylobacter utilizing this technology.
Immuron&rsquo;s second clinical-stage asset, IMM-529, targets <I>Clostridium difficile </I>Infections (CDI). These products together
with the Company&rsquo;s other preclinical pipeline products currently under development targeting immune-related and infectious
diseases are anticipated to meet pressing needs in the global immunotherapy market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For more information visit: http://www.immuron.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>FORWARD-LOOKING STATEMENTS:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release may contain &ldquo;forward-looking
statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product
development programs and any other statements that are not historical facts. Forward-looking statements are based on management&rsquo;s
current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial
condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include:
risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and
relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and
completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers;
our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial
additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described
in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on
which any such statement is based, except as required by law.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">- - - END - - -</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>COMPANY CONTACT:</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Gary S. Jacob, Ph.D.</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ph: +61 (0)3 9824 5254</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">info@immuron.com</P></TD>
    <TD STYLE="width: 37%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AUS INVESTOR RELATIONS:</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Peter Taylor</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NWR Communications</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ph: +61 (0)4 1203 6231</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">peter@nwrcommunications.com.au</P></TD>
    <TD STYLE="width: 31%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>USA INVESTOR RELATIONS:</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dave Gentry - CEO </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">RedChip Companies, Inc.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">US Ph: +1 (407) 491 4498</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">dave@redchip.com</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For more information visit: http://www.immuron.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; border-top: black 1pt solid; padding-top: 3pt; text-align: left; vertical-align: middle">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 3, 62 Lygon Street,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Carlton South, Victoria</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AUSTRALIA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3053</P></TD>
    <TD STYLE="width: 34%; border-top: black 1pt solid; padding-top: 3pt; text-align: center; vertical-align: middle">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">www.immuron.com&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ABN: 80 063 114 045</P></TD>
    <TD STYLE="width: 10%; border-top: black 1pt solid; padding-top: 3pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P></TD>
    <TD STYLE="width: 23%; border-top: black 1pt solid; padding-top: 3pt; text-align: left; vertical-align: middle"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone: + 61 (0)3 9824 5254</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Facsimile: + 61 (0)3 9822 7735</P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !+ $$# 2(  A$! Q$!_\0
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MKDC'+-(!^F0QKU.N+TXHGQ@UM GS2:3:N6]</(/\*[2@ HHHH , T@ %+10
M4444 %%%% '.PZ7<I\0KK5MG^B2Z7%;[\]9%ED./R8?G7148HH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !2 10# 2(  A$! Q$!_\0
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M4G*4%&*<I2BDY+T?]E#_ (.?_P#@GG^T+XCTWP7\4HO'W[*GB76+J*RTV_\
MBU::;J'P[N+RXE\FVM9_B#X8N;VPT=YY&B1;CQ!IVCZ;&SM]HOX40NW]&>F:
MGINM:=8:QHVH6.K:3JEG;ZAIFJ:9=V]_IVHV%Y$EQ:7UA>VLDMM=V=U!(DUO
M<V\LD,\3I)$[(P8_Q_\ QS_X)9_\&_/[67B2X^#G[-/Q8T3]G3X]:O)+I'@S
M6?A?KWBS4_ .K^))3Y=KHU[HOC3[=X*\4QW,Z_9UL-'US2KZ[#O'IM\\S1(U
M7_@CY\;/VLO^"7W[7?B;_@CK^VG'=>+="\2^'M9\=_L:>*(=4=_#_B,:1'>Z
MG>>%?AMKVO20HWAGQII=IJ5SI'A;4[F&Y\'>.-(O?##BSAU2.0\G$_ F0XC
MU\=PO@^)N'\UP>"_M;%<(<88.O@\=BLEBXJMG&1XK%4<.\=A\)S*IC*2=5T<
M/SUG.FJ4SR,MSW(,^P^)Q>09SEF<X?!UJF'Q<\IS#!YI##XBE#GJ4*D\OQ&*
M4:\8>_[%VJ2A[T%4C9O^QBBO.?AE\5_ _P 7=#O-<\$ZL;U=(U>]\.>)='O;
M>;3?$7A+Q1I;*FJ>&/%6AW:QW^B:[ISNGVBRNXE\R&2&[M)+FQN+:YFB^,OQ
M5\+? WX4_$'XO^-;C[-X6^'/A36/%>L,KJDL\&E6DD\=C;%_E-YJ5R(-/LE;
MA[NZ@0_>K\@6!QCQL,N^JU_K]3$4L)#!NE)8B>)KU*-*C1C2:4G.K4Q%"--*
MZFJU*4)2A4A4ET1QV"G@WF,,50G@(T*N)>,A5A+#K#T8U9UJKJQ;BHTHT*_M
M+VE3E1JPG"%2G.E#E_CY^TK\#?V8?![>.?CI\1_#WP^T%W>"P.K7+2:KK=XB
M%_L.@:'9I<ZOK5X1@-#IUE<>3O5[AH8SOK\C]=_X.%/V,=.UF2PT;P7\<_$F
ME12!/[>M?".CZ=;S*#AI8+#5/$5MJ+1=6C,MO#(Z8+11D[1_,-\8?BW^T)_P
M42_:7BU^_L-:\;_$KXCZ\?#WPT^'6E.\MCX3T.>>672?"GA^VD=;33--TBQ4
MW7B#6IO(%S)%?ZSJURRDLO[)^ _^#<OXE:KX,AU'XC?M(>&_"/CJZLUG_P"$
M8\,^"+CQ1X?TFZ>(.MC?>(+W6](NK]XI#Y-U<:=I\4&4+6S3IM9OZLCX0>%'
M .69:_%GBC%PX@S.C&M_9F68FO1I81-Q4X4J& P&/S#$TL/-RH5<QQ7U3!U:
M].M'!TJT*?,_YTEXG>(_&688Y>&_#V&EDN7U'3^OX^A2J5,392<'.MC<7@\%
M1J5Z:C7I8'#^WQ-.C4HRQ%2$IN*_=O\ 9=_X*2_LB?M=WZ>'?A-\3(8?'+6Q
MNC\._&EA/X1\:/$@S*;#3=2(MM;\CDS_ -@WVIF)%,L@2(;Z^[J_SM?VL?V.
M_P!H/]@7XLZ#H/Q =M.O&NCXA^%OQ<\#7M];:/KKZ/<1N-3\.:KMM]2T/Q#H
M\QMI;[1[L1:A9"6&<?:K&>*>3^OW_@DK^V]J?[:'[.!N/'EU;W'QF^$NIVW@
MCXDW$*) /$(>S%UX:\:BV0!()/$FFQRC4HHE$*:WI^IF%8X)(8D^&\4?"+*N
M&\BP/'/ V<SX@X,S"K2I3J5*E/$5\OGB93AAJGUNC1P\<3A*M:G4PE1U\-A<
M;@<9".&Q=)NHIQ^N\//$W,<]S?%\(<7Y7#).*L%"K.%.$9T:6-AAXQG7A+#5
M*E5X?%4Z,X8F"HU\1A,9A92KX:JE3E!_J;1117X$?LX5_G2_'O\ Y/U^*W_9
MW&M_^K5%?Z+5?YTOQ[_Y/U^*W_9W&M_^K5%?U3]%O_D8^(/_ &2E#_U,S$_G
M;Z0O^X<%_P#90U__ %$P9_?'^U#-+;_LS?M"SPR-%-%\#_BK)%(A*NCIX%UU
ME=6'(92 01T-?P]_\$@-"L_$'_!0G]E^VO;);Z+3]5\1^((HFC\U8;W0O 7B
M#4+*^*]%:RN8DN4D(_=2(D@PR@U_<!^U/_R;#^T3_P!D,^*__J":[7\5'_!%
M+_E(K^SS_P!@7XE?^JQ\0UGX(U)4O"CQNJ0;C..3NS3:>O#>:P>JL_AJ36^S
M:ZN]>+4(U/$CPFA)7C+,XIIZK3/LOEL]'K"+U71=D?WI5_*3_P ''WARPM_'
M/[+'BZ.*--3U/PS\2O#-U,JJ)9K#2=1\-:M9QRN%W.EO<:M=M$"Q"&XEV@;V
M)_JVK^6G_@Y&_P"/[]D;_=^+_P#Z+\#5\!]'Z<H>+/"ZBVN>.<TYV;7-"61Y
M@W%V:NFX0;3NGRK316^R\:X1GX;<0<R3Y)Y54C=)VG'-\&E)73LTIR5U9^\]
M>_US_P &]WA73-*_8N\8>*;>&-=5\7?'3QBFJW 0"6:+PYH_AO3=-AD?&YDM
MXI)S&I)"F:0CEVS^[4D<<T;Q2HLD4J-')&ZADDC=2KHZL"K*RDJRD$$$@C!K
M\2_^" ?_ "87/_V77XH?^B?#-?MO7SWB[.=3Q/X[E.3E)<28^";;;4:<<%"G
M%.][0A&,8KHDDK'N^&D(P\/^#XQBHIY#@YM)))RJ/%3FW9:N4I-M]6[NY_G(
MZ)I]MX:_;BTG2='7[)9Z!^UW::=I:1?(+6UT_P",JVUI%%M/R+# B1Q@8"J
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M_3UH]?S4?\$!O^3[[_\ [(AXY_\ 3KX:K^EK_@JJC2?\$\/VL%0$M_PJV[;
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M]8M?RT_\'(W_ !_?LC?[OQ?_ /1?@:OZEJ_"/_@M%^PS^TE^V5<_L]R_L_\
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MUF*\@TOQUX?LM32VU?25^(/V*/BUH/@JU_:>_P""0GQR\6)X*O-7C^+7A/\
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MAZ=#(^'<-2HSJ1]IA:-2<JF'HU:L*$E3PWMJU:EBZ\_R4_X-O/\ D8OVL?\
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M+P[XM\(:-X3_ &9-4\97WB_P_K46LMXB\11^)(K!+1/#;V-G-IJ/;FT<W/\
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M!1XK6+P]2@\=Q=G^/P?/R?[1@\52RV.'Q$.6I/\ =UG1JJ'/R3]R7-3CI?\
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9HH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
